Get App Open
In App
Open App
you are here:

Gland Pharma Ltd.

BSE: 543245 | NSE: GLAND |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE068V01023 | SECTOR: Pharmaceuticals & Drugs

BSE Live

Mar 24, 16:01
1283.25 -11.40 (-0.88%)
Volume
AVERAGE VOLUME
5-Day
45,518
10-Day
52,739
30-Day
32,075
66,852
  • Prev. Close

    1294.65

  • Open Price

    1270.00

  • Bid Price (Qty.)

    1283.25 (10)

  • Offer Price (Qty.)

    1283.25 (10)

NSE Live

Mar 24, 15:59
1282.20 -1.90 (-0.15%)
Volume
AVERAGE VOLUME
5-Day
689,981
10-Day
772,211
30-Day
525,167
1,229,621
  • Prev. Close

    1284.10

  • Open Price

    1275.00

  • Bid Price (Qty.)

    1282.20 (245)

  • Offer Price (Qty.)

    0.00 (0)

Financials

2022 2021 2020 2019 2018
Profit & Loss account of Gland Pharma (in Rs. Cr.) Mar 22 Mar 21 Mar 20 Mar 19 Mar 18  
  12 mths 12 mths 12 mths 12 mths 12 mths  
INCOME  
Revenue From Operations [Gross] 4,384.15 3,423.64 2,571.78 1,993.15 1,583.02  
Less: Excise/Sevice Tax/Other Levies 0.00 0.00 0.00 0.00 2.95  
Revenue From Operations [Net] 4,384.15 3,423.64 2,571.78 1,993.15 1,580.07  
Total Operating Revenues 4,400.71 3,462.88 2,633.24 2,044.20 1,619.94  
Other Income 223.94 134.78 139.17 85.56 48.79  
Total Revenue 4,624.65 3,597.65 2,772.41 2,129.77 1,668.73  
EXPENSES  
Cost Of Materials Consumed 2,046.86 1,749.16 1,090.25 954.89 718.30  
Purchase Of Stock-In Trade 25.67 16.20 18.67 16.28 9.12  
Operating And Direct Expenses 95.05 74.59 78.50 74.03 60.35  
Changes In Inventories Of FG,WIP And Stock-In Trade 36.69 -273.49 -6.90 -114.15 -66.67  
Employee Benefit Expenses 338.57 311.36 277.66 222.95 179.08  
Finance Costs 5.24 3.41 7.18 3.56 4.13  
Depreciation And Amortisation Expenses 110.30 98.78 94.59 81.96 78.21  
Other Expenses 347.23 282.79 219.59 183.89 184.65  
Total Expenses 3,005.61 2,262.80 1,779.54 1,423.41 1,167.17  
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax 1,619.04 1,334.85 992.87 706.36 501.56  
Exceptional Items 0.00 0.00 0.00 -20.00 0.00  
Profit/Loss Before Tax 1,619.04 1,334.85 992.87 686.36 501.56  
Tax Expenses-Continued Operations  
Current Tax 395.88 339.45 251.40 221.23 169.46  
Less: MAT Credit Entitlement 0.00 0.00 0.00 0.00 0.00  
Deferred Tax 14.01 0.12 -31.82 12.00 10.63  
Tax For Earlier Years -3.00 -1.72 0.43 1.23 0.35  
Total Tax Expenses 406.89 337.85 220.01 234.45 180.45  
Profit/Loss After Tax And Before ExtraOrdinary Items 1,212.16 997.01 772.86 451.91 321.11  
Profit/Loss From Continuing Operations 1,212.16 997.01 772.86 451.91 321.11  
Profit/Loss For The Period 1,212.16 997.01 772.86 451.91 321.11  
OTHER ADDITIONAL INFORMATION  
EARNINGS PER SHARE  
Basic EPS (Rs.) 73.84 63.07 49.88 29.16 211.75  
Diluted EPS (Rs.) 73.67 62.99 49.88 29.16 207.24  
VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS  
Imported Raw Materials 0.00 0.00 0.00 0.00 0.00  
Indigenous Raw Materials 0.00 0.00 0.00 0.00 0.00  
STORES, SPARES AND LOOSE TOOLS  
Imported Stores And Spares 0.00 0.00 0.00 0.00 0.00  
Indigenous Stores And Spares 0.00 0.00 0.00 0.00 0.00  
DIVIDEND AND DIVIDEND PERCENTAGE  
Equity Share Dividend 0.00 0.00 0.00 0.00 0.00  
Tax On Dividend 0.00 0.00 0.00 0.00 0.00  
Equity Dividend Rate (%) 0.00 0.00 0.00 0.00 0.00  
Source : Dion Global Solutions Limited

Results of Pharmaceuticals & Drugs Sector

No News.
No News.
No News.
No News.